Currently, out of the existing stock ratings of Kaveri Pohlman - 3 which are a Buy (100%)

Kaveri Pohlman

Work Performance Price Targets & Ratings Chart

Analyst Kaveri Pohlman works at BTIG and is covering the Healthcare sector with 6 price targets and ratings displayed on 4 stocks.

Kaveri Pohlman's average stock forecast success ratio is 25% with an average time for price targets to be met of 59.5 days.

Most recent stock forecast was given on MGNX, MacroGenics at 21-Mar-2023.

Wall Street Analyst Kaveri Pohlman

Analyst best performing recommendations are on MGNX (MACROGENICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 7/11/2022. The price target of $6 was fulfilled within 119 days with a profit of $2.45 (69.01%) receiving and performance score of 5.8.

Average potential price target upside

CTMX CytomX Therapeutics CMPI MGNX MacroGenics ONCS

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Hold

3.19

$1.83 (134.56%)

3.2

1 months 12 days ago

1/5 (20%)

$4.1 (152.00%)

56

Hold

2

$0.64 (47.06%)

16

5 months 24 days ago

0/4 (0%)

$7.25 (47.56%)

Sell

14

10 months 11 days ago

0/1 (0%)

$6.41 (84.45%)

Hold

16

1 years 1 months 16 days ago

0/3 (0%)

$10.39 (174.95%)

Buy

2

$0.64 (47.06%)

10

1 years 2 months 14 days ago

3/6 (50%)

$5.36 (70.73%)

119

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Kaveri Pohlman?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart